Does concurrent use of clopidogrel and PPIs increase CV risk in patients with ACS?
Q: Does concurrent use of clopidogrel and PPIs increase CV risk in patients with ACS? Evidence-based answer: No. Adding a proton pump inhibitor (PPI) in patients taking antiplatelet medications such as clopidogrel for acute coronary syndrome (ACS) doesn't increase the composite risk of cardiovascular (CV) events: CV death, myocardial infarction (MI), and cerebrovascular accident (CVA) (strength of recommendation: B, randomized, controlled trial [RCT] and preponderance of posthoc analyses of large RCTs).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.